In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2
Rana Gbyli, Yuanbin Song, Wei Liu, Yimeng Gao, Giulia Biancon, Namrata S. Chandhok, Xiaman Wang, Xiaoying Fu, Amisha Patel, Ranjini K. Sundaram, Toma Tebaldi, Padmavathi Mamillapalli, Amer M. Zeidan, Richard A. Flavell, Thomas Prébet, Ranjit S. Bindra, Stephanie Halene
Topics & Concepts
OlaparibIDH1Cancer researchMyeloid leukemiaIsocitrate dehydrogenaseNPM1IDH2BiologyClofarabineMyelodysplastic syndromesSynthetic lethalityMutationMutantCytarabinePoly ADP ribose polymeraseImmunologyGeneticsBone marrowPolymeraseGeneEnzymeKaryotypeChromosomeBiochemistryPARP inhibition in cancer therapyDNA Repair MechanismsAcute Myeloid Leukemia Research